What is Ranolazine?
Ranolazine is an antianginal medication that reduces chronic stable angina symptoms by inhibiting the late sodium current in cardiac cells, thereby preventing intracellular calcium overload and reducing myocardial oxygen demand—without affecting heart rate or blood pressure. 1, 2
Drug Classification and Mechanism
Ranolazine is a piperazine derivative structurally related to trimetazidine 1. Its mechanism involves:
- Primary action: Concentration-dependent, voltage-dependent, and frequency-dependent inhibition of the late sodium current (INa, late)
- Downstream effect: By blocking late sodium efflux, ranolazine prevents intracellular calcium overload during ischemia
- Result: Reduced left ventricular wall tension and decreased myocardial oxygen demand 1
The drug also promotes glucose oxidation, improving anaerobic metabolism under ischemic conditions, though the exact contribution of this metabolic effect to its antianginal action remains uncertain 1.
Clinical Indications
Primary indication: Treatment of chronic stable angina as add-on therapy when symptoms are inadequately controlled with beta-blockers and/or calcium channel blockers 3.
The 2024 ESC guidelines recommend ranolazine (Class IIa, Level B) as add-on therapy or as part of initial treatment in properly selected patients 3.
Dosing and Formulation
Available as extended-release tablets in 500 mg and 1000 mg strengths 2. The extended-release formulation facilitates twice-daily administration while maintaining therapeutic plasma concentrations.
Key Clinical Characteristics
Hemodynamic neutrality: Ranolazine produces minimal changes in heart rate (<2 bpm) and systolic blood pressure (<3 mm Hg), making it particularly useful in patients with bradycardia or hypotension where traditional antianginals are contraindicated 1, 2.
Efficacy: Meta-analyses confirm that extended-release ranolazine (500-1000 mg) effectively reduces chronic stable angina symptoms similarly to other currently used antianginal agents 1.
Important Limitations on Outcomes
Critical caveat: While ranolazine improves angina symptoms, it does NOT improve mortality or major cardiovascular outcomes 1:
- The RIVER-PCI trial showed no benefit for death, myocardial infarction, or recurrent angina requiring revascularization in patients with incomplete revascularization
- The MERLIN trial found no benefit for major cardiovascular events in non-ST-segment elevation acute coronary syndrome
Specific Patient Populations Where Ranolazine May Be Preferred
Diabetes mellitus: Ranolazine significantly reduces HbA1c levels, providing dual benefit in diabetic patients with chronic stable angina 1, 4.
Left ventricular hypertrophy: Given its effects on sodium current and calcium homeostasis, ranolazine may be more effective than other drugs in this population 1.
Contraindications to traditional therapy: Patients who cannot tolerate beta-blockers or calcium channel blockers due to bradycardia, hypotension, or reactive airway disease 1.
Safety Profile and Adverse Effects
QT prolongation: Ranolazine causes dose-dependent QTc prolongation (approximately 2.6 msec per 1000 ng/mL plasma concentration). At standard dosing (1000 mg twice daily), mean QTc increase is about 6 msec, though 5% of patients may experience ≥15 msec prolongation 2. Despite this, torsades de pointes has not been reported at recommended therapeutic doses 1.
Contraindications 2:
- Hepatic impairment or liver cirrhosis (QTc prolongation is 3-fold higher in cirrhotic patients)
- Concurrent use with strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, nefazodone, HIV protease inhibitors)
- Pre-existing QT prolongation or long QT syndrome
Renal impairment: Use with extreme caution in moderate to severe renal impairment. A study in severe renal impairment (CrCL <30 mL/min) was stopped early when 2 of 4 subjects developed acute renal failure. Monitor renal function periodically and discontinue if acute renal failure develops 2.
Drug interactions: Ranolazine increases digoxin concentrations; use with caution in patients taking digoxin 1.
Administration
- Take with or without food
- Swallow tablets whole—do NOT crush, break, or chew
- Avoid grapefruit and grapefruit juice (increases ranolazine blood levels) 2
Emerging Applications
While not FDA-approved for these indications, evidence suggests potential benefits in atrial fibrillation, ventricular arrhythmias, and as adjunct therapy in cardio-oncology, though these require further validation in targeted clinical trials 5, 6.